The P®zer compound CP-31398 has been reported to stabilize the core domain of the tumour suppressor p53 in vitro and be an eective anti-cancer drug by virtue of rescuing destabilized mutants of p53. We did not detect any interaction between the p53 core domain and CP-31398 in vitro by a wide range of quantitative biophysical techniques over a wide range of conditions. CP-31398 did not stabilize p53 in our experiments. However, we found that CP-31398 intercalated with DNA and also altered and destabilized the DNA-p53 core domain complex. We analysed by NMR TROSY the interaction of the domain with a DNA oligomer and identi®ed the changes in the complex on the binding of CP-31398. CP-31398 also decreased sequence-speci®c DNA binding of wild-type p53 and His-273 mutant p53. CP-31398 had a non-speci®c toxic eect independent of mutant p53 expression in several cell lines carrying Tetregulated mutant p53. CP-31398 caused a small increase in MDM-2 expression and a more pronounced p53-independent increase in Bax expression. CP-31398 did, however, induce the PAb1620 epitope (characteristic of native p53) in cells expressing His-175 mutant p53. This was prevented by cycloheximide, suggesting that any stabilizing action of CP-31398 would have to be on newly synthesized p53. One of the unstable mutants that was reported to have been rescued by CP-31398, R249S, does not bind DNA when folded at lower temperatures.
Introduction
The tumour suppressor p53 is a very promising target for anti-cancer therapies (Bullock and Fersht, 2001 ). The observations that p53 is frequently inactivated by missense mutation in a wide variety of cancers (Hollstein et al., 1991; Ko and Prives, 1996) and that the rescue of mutant p53 conformation and function can suppress tumour growth (Foster et al., 1999) suggest that reactivation of mutated p53 may be an eective therapy. p53 is a tetramer whose structure has been dissected and expressed as individual domains of the monomeric unit (Bullock et al., 1997; Jayaraman et al., 1997; Lee et al., 1994) . The vast majority of inactivating mutations map to the core or DNA-binding domain of p53 (Ko and Prives, 1996) . The crystal structure of wild-type core domain complexed with DNA (Cho et al., 1994) provides a structural basis for analysing the eects of mutation. Mutational and nuclear magnetic resonance (NMR) studies in solution (Wong et al., 1999) show that oncogenic mutations can cause longer range conformational changes in the domain that are not readily predictable from the structure. Biophysical studies have shown that a signi®cant number of oncogenic mutations inactivate p53 simply by reducing the melting temperature of the core domain below body temperature (Bullock et al., 1997 (Bullock et al., , 2000 Nikolova et al., 1998) and that, in theory, the activity of such mutants could be restored by small molecule drugs that speci®cally bind to the native state. Foster et al. (1999) reported from an antibody assay, that a class of small synthetic compounds, including CP-31398, stabilizes p53 core domain. CP-31398 also causes regression of tumours that have inactivated p53. Those compounds should, therefore, be important lead compounds for drug design for a novel form of anti-cancer therapy.
Because of the potentially profound importance of this novel therapy, our two laboratories have independently investigated the eects of CP-31398 in depth. The Cambridge laboratory attempted to locate by NMR the binding site for CP-31398 in the core domain to provide a structural basis for rational drug design. The Stockholm laboratory attempted to discover in more detail the mode of action. We found no evidence that CP-31398 binds to p53 core domain in vitro or restores p53-dependent tumour suppression in living cells. However, we found evidence that CP-31398 may induce newly synthesized p53 to produce a native epitope in the presence of pAb1620.
Results

NMR analysis of p53 core domain in presence of CP-31398
HSQC spectra, of free core domain and its complex with DNA were recorded in NaPO i buer in the absence and presence of CP-31398. The chemical shift dierences (DdH and DdN), which sensitively probe changes in the chemical environment of residues, were calculated and plotted against residue number. Shift dierences greater than 0.05 p.p.m. for DdH and 0.25 p.p.m. for DdN were considered signi®cant (Wong et al., 1999) and are shown in Figure 1a ,b.
The presence of a large excess of CP-31398 (up to 2.7 mM) had no eect on the wt p53 core domain (data not shown), which strongly indicates a lack of any interaction. This result was obtained in NaPO i and HEPES buer and CP-31398 was pre-dissolved in both DMSO and methanol to exclude organic buer eects. N spectrum of the hot-spot mutant R249S upon addition of CP-31398 in NaPO i buer.
The absence of any direct interaction between p53 core domain and CP-31398 prompted us to investigate the eect of CP-31398 on the p53-DNA complex (see alsō uorescence results). This was examined by comparing the spectra of core domain-DNA complex with and without of CP-31398. Upon addition of CP-31398, many peaks shifted back to positions seen in the unbound core domain spectrum: L137, R181, S241, G244, R273, V274, R279, and N288. These residues are¯anked by partially reverted shifts: G117, V197, I255, R282 and R283.
Other residues, however, were not aected by the compound. The majority of these are removed from the DNA-binding surface: G112, A129, L130, V147, T150, A159, C176, D186, A189, R202, T211, H214, V216, Y220, Y234, M237, N239, L257, D259, S269 and E287. The remaining residues that are not aected by CP-31398 lie in the Zn 2+ -binding loops 2 and 3, on opposite sides of the Zn 2+ to the DNA binding surface (C176, M237 and N239) and in and around helix 2 (S121, V122, E287). Figure 1 Chemical shift analysis of the eects of CP-31398. White bars represent residues that disappeared completely or were shifted so far that re-assignments was not possible; their values were ®xed arbitrarily (0.122 p.p.m. for DdH, 0.766 p.p.m. for DdN). The secondary structure assignment is taken from the crystal structure (Cho et al., 1994) Some signals shifted upon addition of CP-31398 but were unaected by DNA binding: R110, Y126, M160, H178, L188, R290 and, to an extent, E224 (data not shown). Figure 2 shows the changes seen upon adding CP-31398 to the p53-DNA complex superimposed on the crystal structure (Cho et al., 1994) .
Effects of CP31398 on apparent T m of the p53 core domain
Under similar conditions to those used in the NMR experiments (Figure 3a) , we found that 20mer DNA raised the apparent T m of the core domain from 42.9 to 48.88C (cf. values in Tris buer: (Bullock et al., 1997) ). Random 20mer DNA did not elicit the same eect. But, we were, however unable to detect any stabilization of p53 core domain by CP-31398. Using both Foster et al.'s HEPES buer and NaPO i buer, repeated measurements showed no eect of CP-31398 ( Figure 3b) . As a positive control, we added heparin, a small DNA mimic, to p53, which did stabilize p53 core domain by 1.28C, as expected. Further, CP-31398 lowered the apparent T m of the core-DNA complex by 1.78C to 47.18C (Figure 3a) . 
Fluorescence assays on CP-31398 binding
Fluorescence spectra of CP-31398 did not change when 32 mM (fourfold excess) core domain was added ( Figure  4a ), in both HEPES and NaPO i buer. Further, measurements of¯uorescence anisotropy, a procedure that does not rely on changes of¯uorescence intensity or wavelength, failed to detect binding of CP-31398. The addition of DNA to CP-31398 did, however, have a dramatic eect on its spectrum (Figure 4b ) and, interestingly, this eect was partly reversed when p53 core domain was included in the compound/DNA mixture. In order to make sure that the¯uorescence increase upon adding DNA and protein to CP-31398 was not due to CP-31398 binding residual free DNA, an excess (32 : 20 mM binding sites) of protein over DNA was used. Thus it seems that CP-31398 interacts with DNA even when it is bound to p53. Presumably CP-31398 is a DNA intercalator.
Stability of CP-31398
We noticed that CP-31398 degraded over time. This was ®rst apparent from the compound's 1D NMR spectrum, which acquired new peaks as samples aged. This eect was observed irrespective of whether the compound was dissolved in DMSO-d 6 or MeOD and irrespective of whether it was stored in organic solvent only or further dissolved in aqueous solution. CP-31398 that was stored as a solid at 7208C and was freshly dissolved always showed the same spectrum with the correct number of signals. The degradation of CP-31398 over time was con®rmed by mass spectrometry (data not shown). Whereas fresh sample The eect of 12mer DNA on the¯uorescence of CP-31398 is remarkable. Not only does the intensity increase ®vefold, but the peak maximum also shifts to slightly higher wavelength. This eect is partially reversed by addition of p53 core domain. Concentrations were chosen such that, after binding p53 core domain, no free 12mer would be left in solution showed a strong molecular peak at 363.2 m/z with only a small (57%) peak at 245.1 m/z, samples that were stored at room temperature for 3 ± 4 days exhibited a main peak at 191.0 m/z and signi®cant fragmentation patterns between 139.0 and 349.1 m/z as well as the reduced molecular ion at 363.2 m/z. All spectra were acquired under identical conditions. We accordingly always used freshly prepared samples in the above experiments.
In case degradation products of CP-31398 were responsible for its observed aects by Foster et al. (1999) we repeated the T m and NMR experiments with aged samples; but the results were the same.
Inhibition of DNA binding by CP-31398
The eect of CP-31398 on sequence-speci®c DNA binding of p53 was assessed in band shift assays using cellular extracts as a source of wild-type (wt) and mutant p53 proteins. Wild-type p53 protein from MCF7 cells formed a complex with a labelled probe containing a p53 binding site ( Figure 5a , lane 1), which was further enhanced by PAb421 antibody (Figure 5a , lane 2). Incubation of wtp53 with increasing concentrations of CP-31398 did not stimulate the DNA binding of p53. In contrast, strong inhibition of the formation of wtp53/DNA complex was observed ( Figure 5a , lanes 3 ± 5). Sequence-speci®c DNA binding activity of the His-273 mutant p53 from SW480 cells was stimulated by PAb421 antibody (Figure 5a , lanes 7 and 8). However, CP-31398 inhibited formation of the mutant p53/DNA complex in a concentration-dependent manner (Figure 5a , lanes 9 ± 11). The eect of CP-31398 on DNA binding of mutant p53 proteins was assessed also in the absence of activating antibody PAb421 (Figure 5b ). DNA binding of p53 mutants His-175 and Trp-282 from CW678 and BL60 cells, respectively, was not induced by CP-31398. Further, the disruption of additional (nonspeci®c) DNA/protein complexes formed by DNA-binding proteins from cellular extract was observed (Figure 5a , lanes 3 ± 5 and 9 ± 11, and Figure 5b , lanes 2 ± 4 and 6 ± 8). Interestingly, in the absence of cellular extract, CP-31398 was able to cause the retardation of a labelled DNA probe, indicating that it interacts with DNA ( Figure 6 ).
CP-31398 suppressed the growth of tumour cells in a p53-independent manner
We next assessed the eect of CP-31398 on the growth of tumour cells in the presence or absence of expression of mutant p53, using Saos-2-His-273 and SKOV-His-175 cells carrying tetracycline-regulated mutant p53. The growth of both cell lines was suppressed by CP-31398 at 5 mM (Figure 7) . Growth suppression reached 90% in both cell lines at 20 mM. However, the eect of CP-31398 did not depend on the presence of mutant p53. Moreover, the growth of SKOV-His-175 was suppressed by CP-31398 more eciently in the absence of mutant p53 expression. CP-31398 caused over 80% growth suppression of non-transformed human ®bro-blasts immortalized with hTERT (Clontech, Palo Alto, CA, USA) at a concentration of 10 mM.
Induction of p53 target genes by CP-31398 does not depend on mutant p53 expression
Next we examined whether treatment with CP-31398 can induce the p53 target genes Bax and MDM-2 in a (Figure 8a ). MDM-2 was not induced by CP-31398 in the absence of p53 expression. CP-31398 treatment caused a marked induction of Bax expression. However, this eect did not depend on mutant p53 expression, since it was observed also in the absence of p53 expression (in the presence of doxycycline) (Figure 8a,b) .
CP-31398-mediated restoration of wild-type conformation of His-175 mutant p53 requires protein synthesis CP-31398 was originally identi®ed based on its ability to protect mutant p53 from thermal denaturation, thus preserving the wild-type conformation. It was suggested that only newly synthesized p53 protein should be amenable to stabilization by CP-31398 (Foster et al., 1999) . In order to test this idea, we examined the induction of the wild-type-speci®c epitope detected by the monoclonal antibody PAb1620 by CP-31398. As shown in Figure 9 , treatment of SKOV-His-175 cells with 10 mM of CP-31398 resulted in the appearance of PAb1620-positive cells. The total levels of p53 appeared to be unaected by the treatment, as judged from immunostaining with a polyclonal anti-p53 antibody. Interestingly, treatment with cycloheximide prevented the induction of wild-type p53 conformation in SKOV-His-175 cells by CP-31398 ( Figure 10 ). This indicates that CP-31398 may be able to rescue the wildtype conformation of newly synthesized mutant p53 in living cells.
Discussion
Failure to detect binding of CP-31398 to p53 core domain in vitro
The binding of ligands of p53 core domain generally causes changes in chemical shifts in its NMR spectrum in the ligand binding site, and we use these changes routinely to detect binding and locate the binding sites. The addition of CP-31398 to a concentration of 2.7 mM had no detectable eects whatsoever on the chemical shifts of p53. A set of 1 D spectra of the compound recorded in presence and absence of p53 core domain also gave no evidence of binding. Similarly, we were unable to detect any evidence from the¯uorescence spectrum of CP-31398 in the presence of 32 mM core domain, either from quenching, perturbation or emission spectrum or anisotropy (Figure 4) . Further, the presence of CP-31398 did not increase the T m of the core domain (Figure 3 ). Even if CP-31398 was able to bind to the core domain in a spectroscopically silent manner, the binding would still Figure 6 CP-31398 induced retardation of a radiolabelled DNA probe in a native gel. Ten mg of CP-31398 were incubated with the labelled DNA probe for 30 min and applied on a native gel Figure 7 p53-independent growth suppression by CP-31398. The growth of Saos-2-His-273 and SKOV-His-175 cells in the presence of CP-31398 was assessed using the WST-1 cell proliferation reagent. Expression of mutant p53 in both cell lines was induced by doxycyclin withdrawal have to increase the¯uorescence anisotropy of the small molecule (a technique we routinely use to monitor the binding to p53) and to raise the T m .
Thus, we conclude that there is no detectable binding of CP-31398 to the p53 core domain at concentrations up to nearly 3 mM under a variety of conditions. 
CP-31398 partially reversed DNA binding and destabilizes the core/DNA complex
The binding of CP-31398 to DNA weakened the DNAcore domain interactions; the T m of the protein/DNA complex was lowered (Figure 3) . Fluorescence measurements (Figure 4b ) that indicated that not only did CP-31398 intercalate into free DNA but it remained bound even when the DNA was complexed with p53.
Comparative NMR experiments on the protein/ DNA complex in presence of CP-31398 give an idea of how the complex is weakened by the binding of the drug. First, apparent molecular weight of the p53-DNA complex, based on population-averaged relaxation properties, appeared to be lower in the presence of CP-31398. This could indicate that the compound induces a 1 : 1 protein : DNA complex. L137, R181, S241, G244, R273, V274, R279, and N288, which revered to`unbound p53' shifts all lie on the DNA binding surface, which indicated that most of the contacts between the protein and the DNA were lost. Crucially, though, some residues retain their`DNAbinding' environments (S121, V122, and residues in helix 2). Thus it seems likely that the unobservable residue K120, which is the only residue that makes DNA backbone contact, was still bound and that helix 2 was inserted partially into the major groove. This is supported by the fact that G117, A129 and L130 were also unaected by CP-31398 ± loop 1 and strand 2 therefore retain overall DNA-binding conformation.
Closer examination of the group of residues that cluster around the Zn 2+ ion, showed that they fall neatly into two categories: those on the DNA binding surface that revert to the`unbound' shifts upon addition of CP-31398 and those on the opposite side of the Zn 2+ , which retain their`DNA-bound' shifts. The signals from b scaold residues that are known to shift when p53 binds DNA (data not shown) are also not aected by the addition of CP-31398 to the p53-DNA complex. Consistent with the DSC and¯uorescence data, the NMR suggested therefore, that, in the presence of CP-31398, the core can loosely bind DNA but many of the direct interactions are abrogated.
Binding to full-length p53
Band-shift assays showed that CP-31398 disrupted sequence-speci®c DNA binding of wild-type and of His-273 mutant p53 that was induced by the PAb421 antibody. We did not observe reactivation of speci®c DNA binding of p53 mutant proteins in the absence of reactivating antibody PAb421 either. Moreover, as evident from the band shift experiments, the formation of non-p53-mediated protein/DNA complexes was inhibited by CP-31398. Our observation that CP-31398 caused retardation of a labelled probe on a native gel indicates that the suppression of DNA binding by CP-31398 might be due to its interaction with DNA, consistent with the NMR data.
p53-independent suppression of growth
Our experiments demonstrated that although CP-31398 eciently suppresses the growth of tumour cells, it acts through p53-independent mechanisms. It is possible that CP-31398 targets other cellular proteins besides p53 and thus has an eect in the absence of p53. One possible mechanism of growth suppression by CP-31398 could be stimulation of Bax expression. CP-31398-mediated induction of Bax is independent of the presence of mutant p53, and could, therefore, at least partially account for the p53-independent eects of CP-31398. The induction of MDM-2 by CP-31398 was p53-dependent but rather weak. It is well established that MDM-2 targets p53 for degradation (Asker et al., 1999; Prives and Hall, 1999) . However, we did not observe any reduction in p53 levels after CP-31398 treatment. The amount of MDM-2 induced after CP-31398 treatment is presumably insucient for p53 degradation. In conclusion, it appears that CP-31398 may induce the p53 pathway to some extent in living cells, but this process probably plays quite a minor role in growth suppression by CP-31398.
Induction of native epitope during biosynthesis
We observed an induction of the wild-type-speci®c PAb1620 epitope upon treatment with CP-31398, which is consistent with the results reported by Foster et al. (1999) . Notably, cycloheximide treatment prevented the induction of PAb1620-positive p53 by CP-31398. If CP-31398 acts by preventing thermal denaturation of mutant p53, it would have to do so by stabilizing the conformation of only newly synthesized mutant p53 protein. Foster et al. (1999) , reported that CP-31398 inhibited by 75% the growth in mice of the human melanoma xenograft A375.S2, which is mutated at position 249. It has been shown that the main reason for the inactivity of the hotspot mutant R249S is not that it is destabilized but that it is distorted Wong et al., 1999) and does not bind sequence-speci®c DNA (Bullock et al., 2000; Nikolova et al., 2000) . The distortion is basically localized, and can be reversed by the mutation of H168, which is in close contact, to R168. Thus, if CP-31398 is able to reactive R249S in vivo, it would have to be during biosynthesis, and the binding retained afterwards irreversibly. We failed to see binding of CP-31398 to the mutant R249S in our NMR experiments.
Conclusions
The experiments in this study show that CP-31398 has no detectable binding to wild-type or mutant R249S p53 core domain under a wide range of concentrations and no binding to full-length p53. Perhaps CP-31398 can bind to p53 during its biosynthesis and before it is fully folded. It would thus have to be incorporated into p53 and not dissociate. This mechanism remains to be established.
Our experiments show that CP-31398 has rather strong p53-independent activity, which might result from its toxicity as an intercalating drug. Nonspeci®c eects of CP-31398 could probably override its p53-speci®c activity in cells. Attempts should be made to identify more speci®c and less toxic analogues of CP-31398.
Materials and methods
Reagents and cell lines
Core domain of human p53, corresponding to residues 94-312, was expressed and puri®ed (Bullock et al., 1997; Wong et al., 1999) . DNA oligomers were synthetized and then puri®ed by reverse phase chromatography. All oligomers were palindromic and contained the following sequences: 12mer: GGAACATGTTCC and 20mer: GAACATGTTC-GAACATGTTC which are derived from the p53 consensus binding site. Double-stranded 12mer and 20mer contain two and four p53 binding sites respectively. In addition, two nonspeci®c sequences were used: ran12mer: TCCTGATCAGGA and ran20mer: TACTTCCTGATCAGGAAGTA. All oligomers were annealed by heating them to 958C for 5 min. The sample of CP-31398 (M r =362.5) that was used for the biophysical studies in Cambridge was donated by Cambridge Drug Discovery (Cambridge, UK). Its structure was con®rmed by NMR and mass spectrometry. The compound was weighed out and freshly dissolved in dimethyl sulfoxide (DMSO) before each experiment to a concentration of 10 mg ml
71
, unless stated otherwise, as it was found to be unstable. The sample of CP-31398 that was used in Stockholm was kindly donated by P®zer (Dr Farzan Rastinejad).
Anti-p53 mouse monoclonal antibodies, PAb1620, Pab240, and PAb1801 were obtained from Calbiochem (Darmstadt, Oncogene Characterization of the p53-rescue drug CP-31398 TM Rippin et al Germany). Anti-p53 rabbit polyclonal antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-MDM-2 mouse monoclonal antibody was from Neo Markers (Fremont, CA, USA) and anti-Bax rabbit polyclonal antibody was from Becton Dickinson (Franklin Lakes, NJ, USA). Secondary antibodies, horse anti-mouse conjugated with FITC, goat anti-rabbit conjugated with Texas Red were obtained from Vector (Burlingame, CA, USA). All other reagents we obtained from Sigma-Aldrich Sweden AB (Stockholm, Sweden). Human osteosarcoma Saos-2-His-273 (obtained from M Fritsche, Germany) and ovarian carcinoma SKOV-His-175 (provided by P Chumakov, Engelhardt Institute of Molecular Biology, Moscow, Russia) expressed indicated mutant p53 proteins under the control of tetracycline-dependent promoter. Cell lines were cultured in Iscove's Modi®ed Dulbecco's medium supplemented with 10% fetal bovine serum and 50 mg/ml of gentamycin (Invitrogen tm Life Technologies, Groningen, The Netherlands).
Buffer conditions for biophysical studies
Two buers were used throughout: a phosphate buer containing 25 mM NaPO i (pH 7.2), 150 mM KCl and 5 mM dithiothreitol (DTT) and a HEPES buer containing 25 mM HEPES (pH 6.8), 150 mM KCl and 10 mM DTT. In all experiments involving CP-31398, the equivalent amount of solvent used to dissolve CP-31398 was added to all control experiments. In all DSC experiments, a DTT concentration of 1 mM was used in both buer systems.
Nuclear magnetic resonance
All spectra were acquired with a Bruker DRX 600 MHz spectrometer equipped with a TXI triple resonance probe and z-gradients at 293 K.
1 H-
15
N and 1 H-13 C heteronuclear correlation spectra (HSQCs) were recorded in HEPES and NaPO i , buer. In all HSQC experiments, concentrations of p53 core domain, 12mer DNA and CP-31398 were approximately 250 mM, 150 mM and 2.7 mM respectively. Shifts that occurred upon DNA or CP-31398 binding, were analysed by chemical shift analysis in both the 1 H and 15 N dimension. Where signals from one residue split, the average shift used and if peaks disappeared or shifts were so great that assignment was not possible, an arbitrary shift value was plotted (0.122 for DdH, 0.766 for DdN).
Differential scanning calorimetry (DSC)
Solutions of p53 core domain were heated in a VP-DSC (Microcal) at a rate of 60 K h 71 from 10 to 908C after a 5 or 10 min pre-equilibration at 108C. Final protein concentrations were 10 ± 15 mM. 20mer DNA was added at an equimolar concentration and ®nal CP-31398 concentrations were 125 mM. Final concentration of heparin (from bovine intestinal mucosa, Fluka) was 4 mg ml 71 . Apparent melting temperatures (T m ) were read from the traces after a baseline (run with buer only) had been subtracted. Repeated runs reproduced T m s to within +0.28C.
Fluorescence spectrosocopy
Spectra were recorded on an Aminco Bowman Series 2 Luminescence Spectrometer. CP-31398 (9 mM) was excited at 313 or 326 nm and emission data was collected from 340 to 600 nm at 293 K. Spectra were acquired in HEPES and NaPO i buer in the presence and absence of 32 mM core domain and/or 10 mM 12mer DNA.
Mass spectrometry
Spectra were all acquired under identical circumstances on a Micromass Q-TOF mass spectrometer. Samples were either freshly dissolved in DMSO or had been kept at room temperature in DMSO or DMSO/water for several days.
DNA binding assay to full-length p53
Band shift assays were performed as described (Selivanova et al., 1996) .
Growth suppression assay
Saos-2-His-273 or SKOV-His-175 cells were cultured in 96-well plates at a density of 3000 cells per well in a total volume of 100 ml with or without doxycycline. After 48 h of incubation with CP-31398 the cell proliferation reagent WST-1 (Roche Diagnostics GmbH, Germany) was added to the cells. The degree of WST-1 reduction is proportional to the number of living cells. We measured absorbance of samples by a microplate reader (Bio-Rad Model 550) at l490 nm according to the manufacturer's recommendations.
Immunostaining SKOV-His-175 cells were plated in 16-well chamber slides (Nalge Nunc International, Napervill, IL, USA) at a density of 3000 cells per well and treated with 5 or 10 mM or CP-31398. After 24 h of incubation cells were ®xed and stained with antibodies against MDM-2 and Bax according to standard procedures.
Treatment with cycloheximide
SKOV-His-175 cells were plated in 16-well chamber slides and treated with cycloheximide at a concentration of 1 mg/ml for 1 h. CP-31398 (10 mM) was added and incubation was continued for 15 h. Cells were ®xed and stained with PAb1620 and Hoechst.
